Searchable abstracts of presentations at key conferences in endocrinology

Endocrine Abstracts

Published by BioScientifica

Page 1 of about 1 results

ea0081ep221 | Calcium and Bone | ECE2022

IPN60130 for the treatment of fibrodysplasia ossificans progressiva: methodology of the randomized, double-blind, placebo-controlled phase II FALKON trial

Karimian Negar , Powell Christine , Shih Fei

Objectives: Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare genetic disorder caused by activin receptor-like kinase-2/activin A receptor type 1 (ALK2/ACVR1) mutation and characterized by heterotopic ossification (HO) inducing progressive restriction of mobility. IPN60130 is a selective ALK2/ACVR1 inhibitor being investigated for the treatment of FOP.1 Here, we describe methodology of the FALKON trial (NCT05039515) designed to compare efficacy a...
0 shares

Published by BioScientifica

Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 | Privacy policy | Cookie settings

BiosciAbstracts

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more